Beyond the approvals of both Provenge and Yervoy, there are a number of additional catalysts that could ignite further interest in the field of cancer immunotherapy.
Similarities Between Two Immunotherapies in Cancer
March 30, 2011 By 1 Comment
Approval of Bristol-Myers Squibb’s Yervoy® [ipilimumab] for melanoma in March 2011 marked the second victory for the field of immunotherapy in oncology within a year.
Five Key Factors Weighing on Dendreon
July 1, 2010 By Leave a Comment
Shares of Dendreon Corporation (DNDN) have declined significantly from an all-time high of $57.67 in late April 2010 when the company received U.S. Food and Drug Administration [FDA] approval for Provenge® [sipuleucel-T], the first active immunotherapy approved for the treatment of cancer in the U.S. Today, shares of Dendreon traded as low as $28.01, down [...]
Cancer Vaccine Therapies: Failures and Future Opportunities
April 7, 2010 By 3 Comments
(Note: the following text is an Executive Summary from our new 150-page report titled “Cancer Vaccine Therapies: Failures and Future Opportunities”) Since the early 1990s, cancer immunotherapy has provided hope to patients, physicians, and investors as a new treatment modality with limited side effects and superior efficacy. Cancer immunotherapy broadly includes passive immunization, active immunization, [...]
Much Ado About Medarex
June 24, 2009 By Leave a Comment
According to their website, Discovery’s Edge is the Mayo Clinic’s online research magazine that is designed to communicate the story of scientists and researchers who are bringing treatments and improved care to patients and also reports on “works–in–progress.” Through this publication, Mayo investigators studying immunotherapy for aggressive prostate cancer reported over the past weekend that [...]
Follow MD Becker Partners